HRTX - Heron Therapeutics Inc Stock Price, Fair Value and News

3.20USD-0.02 (-0.62%)Market Closed

Market Summary

USD3.20-0.02

Market Closed

-0.62%

HRTX Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

HRTX Stock Price

View Fullscreen

HRTX RSI Chart

HRTX Valuation

Market Cap

482.1M

Price/Earnings (Trailing)

-5.96

Price/Sales (Trailing)

3.65

EV/EBITDA

-87.4

Price/Free Cashflow

-10.73

HRTX Price/Sales (Trailing)

HRTX Profitability

EBT Margin

-8.66%

Return on Equity

239.74%

Return on Assets

-37.15%

Free Cashflow Yield

-9.32%

HRTX Fundamentals

HRTX Revenue

Revenue (TTM)

132.1M

Rev. Growth (Yr)

17.07%

Rev. Growth (Qtr)

1.28%

HRTX Earnings

Earnings (TTM)

-81.0M

Earnings Growth (Yr)

90.36%

Earnings Growth (Qtr)

70.53%

Breaking Down HRTX Revenue

Last 7 days

15.5%

Last 30 days

15.5%

Last 90 days

11.5%

Trailing 12 Months

166.7%

How does HRTX drawdown profile look like?

HRTX Financial Health

Current Ratio

2.47

HRTX Investor Care

Shares Dilution (1Y)

25.84%

Diluted EPS (TTM)

-0.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	132.1M	0	0	0
2023	113.8M	118.0M	122.8M	127.0M
2022	89.8M	95.0M	98.3M	107.7M
2021	83.3M	83.0M	86.3M	86.3M
2020	139.8M	125.8M	103.1M	88.6M
2019	97.5M	116.9M	139.7M	146.0M
2018	38.7M	47.5M	58.7M	77.5M
2017	4.9M	13.4M	22.0M	30.8M
2016	0	0	0	1.5M
2011	1.5M	1.2M	825.0K	646.0K
2010	0	1.3M	1.3M	1.3M
2009	0	0	0	1.3M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Heron Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	forbes william p	acquired	-	-	3,874	evp, chief development officer
Apr 19, 2024	duarte ira	acquired	-	-	3,874	evp, chief financial officer
Apr 19, 2024	duarte ira	sold (taxes)	-2,962	2.64	-1,122	evp, chief financial officer
Apr 19, 2024	collard craig a	acquired	-	-	13,797	chief executive officer
Apr 03, 2024	collard craig a	acquired	-	-	62,500	chief executive officer
Jan 19, 2024	johnson craig a	acquired	-	-	13,948	-
Jan 19, 2024	christian waage	acquired	-	-	13,948	-
Jan 19, 2024	rodriguez susan	acquired	-	-	13,948	-
Jan 19, 2024	dissanaike sharmila	acquired	-	-	13,948	-
Jan 19, 2024	morgan adam	acquired	-	-	13,948	-

Which funds bought or sold HRTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	B. Riley Wealth Advisors, Inc.	sold off	-100	-19,533	-	-%
May 16, 2024	JANE STREET GROUP, LLC	added	61.15	460,429	743,642	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.93	-140	28,833	-%
May 16, 2024	COMERICA BANK	reduced	-20.96	172	772	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	26.04	334,053	651,066	-%
May 15, 2024	Capital Planning Advisors, LLC	added	60.88	109,342	176,781	0.03%
May 15, 2024	Engineers Gate Manager LP	added	9.82	91,820	208,132	-%
May 15, 2024	TANG CAPITAL MANAGEMENT LLC	unchanged	-	1,979,500	5,124,500	0.53%
May 15, 2024	CAROLINAS WEALTH CONSULTING LLC	new	-	54,569	54,569	0.01%
May 15, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	15.39	38,000	83,000	-%

Are Funds Buying or Selling HRTX?

Are funds buying HRTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HRTX

No. of Funds

Unveiling Heron Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	0%	0	SC 13G/A
Feb 14, 2024	great point partners llc	0%	0	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	4.99%	7,881,933	SC 13G/A
Feb 13, 2024	vanguard group inc	5.56%	8,338,912	SC 13G/A
Feb 06, 2024	franklin resources inc	4.3%	6,404,795	SC 13G/A
Dec 07, 2023	jpmorgan chase & co	0.0%	84,549	SC 13G/A
Dec 06, 2023	blackrock inc.	4.7%	7,037,314	SC 13G/A
Jul 25, 2023	rubric capital management lp	19.0%	26,713,503	SC 13D/A
Apr 13, 2023	great point partners llc	5.35%	6,360,161	SC 13G
Feb 22, 2023	rubric capital management lp	9.9%	11,750,000	SC 13D/A

Recent SEC filings of Heron Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 07, 2024	8-K	Current Report
May 07, 2024	10-Q	Quarterly Report
Apr 29, 2024	DEF 14A	DEF 14A
Apr 29, 2024	ARS	ARS
Apr 19, 2024	PRE 14A	PRE 14A
Apr 19, 2024	4	Insider Trading
Apr 19, 2024	4	Insider Trading
Apr 19, 2024	4	Insider Trading
Apr 05, 2024	4	Insider Trading
Mar 21, 2024	8-K	Current Report

Peers (Alternatives to Heron Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Heron Therapeutics Inc News

Latest updates

Heron Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	1.3%	34,670	34,233	31,434	31,762	29,615	30,028	26,557	27,630	23,457	20,655	23,230	22,443	20,018	20,605	19,965	22,668	25,400	35,083	42,624	36,659	31,602
Gross Profit	7.7%	26,226	24,348	13,226	-	12,761	-	11,840	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	93.2%	31,024	16,062	38,155	74,165	62,678	23,991	53,722	77,128	86,380	74,192	74,938	82,912	72,132	81,901	78,349	78,417	78,134	94,445	77,477	88,438	96,302
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	96,302
S&GA Expenses	-7.2%	11,442	12,328	12,956	21,205	21,154	17,775	18,378	22,938	23,422	24,487	25,206	22,250	15,236	15,553	12,515	15,589	20,196	20,420	16,977	23,647	28,720
R&D Expenses	-57.9%	4,608	10,950	13,558	17,572	13,817	11,057	25,545	28,834	42,070	28,877	28,595	35,233	38,116	44,453	49,182	44,004	36,894	48,277	34,708	41,425	42,972
EBITDA Margin	3.2%	-0.04*	-0.04*	-0.05*	-0.05*	-0.05*	-0.06*	-0.06*	-0.06*	-0.07*	-0.07*	-0.08*	-0.08*	-	-	-	-	-	-	-	-	-
Interest Expenses	-74.8%	649	2,580	163	-	-	1,349	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	3.8%	-0.09*	-0.09*	-0.09*	-0.10*	-0.10*	-0.11*	-0.12*	-0.12*	-0.13*	-0.13*	-0.13*	-0.14*	-	-	-	-	-	-	-	-	-
Net Income	70.5%	-3,160	-10,724	-25,008	-42,059	-32,768	-19,869	-41,908	-56,359	-63,888	-54,646	-52,408	-61,015	-52,614	-62,281	-58,228	-55,190	-51,579	-57,920	-33,595	-50,222	-63,012
Net Income Margin	29.6%	-0.61*	-0.87*	-0.97*	-1.16*	-1.33*	-1.69*	-2.21*	-2.39*	-2.58*	-2.56*	-2.65*	-2.82*	-	-	-	-	-	-	-	-	-
Free Cashflow	-542.9%	-9,766	2,205	-9,972	-27,443	-25,124	-37,948	-37,111	-28,695	-44,983	-45,648	-54,697	-63,307	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.1%	218	223	229	201	221	251	272	244	274	306	352	404	311	354	390	433	479	513	393	412	436
Current Assets	-1.5%	186	189	194	165	178	205	224	194	223	254	315	367	272	314	351	393	438	479	364	381	406
Cash Equivalents	-28.7%	20.00	29.00	35.00	13.00	27.00	15.00	50.00	49.00	57.00	91.00	160	191	60.00	105	95.00	81.00	103	72.00	60.00	53.00	23.00
Inventory	0.9%	42.00	42.00	42.00	45.00	52.00	55.00	52.00	61.00	56.00	48.00	42.00	43.00	43.00	42.00	43.00	41.00	35.00	25.00	24.00	29.00	31.00
Net PPE	-4.3%	19.00	20.00	21.00	21.00	22.00	22.00	23.00	23.00	24.00	24.00	23.00	22.00	23.00	23.00	22.00	22.00	22.00	20.00	16.00	18.00	16.00
Liabilities	-1.9%	252	256	257	241	232	237	250	266	250	228	234	244	115	117	113	109	113	109	108	106	104
Current Liabilities	-5.4%	75.00	80.00	80.00	87.00	78.00	82.00	94.00	109	93.00	71.00	72.00	82.00	101	103	98.00	93.00	97.00	97.00	97.00	95.00	92.00
Shareholder's Equity	0.6%	-33.77	-33.97	-	-	-11.43	14.00	22.00	-	24.00	78.00	119	160	196	236	277	324	365	404	285	305	332
Retained Earnings	-0.2%	-1,909	-1,906	-1,895	-1,870	-1,800	-1,795	-1,775	-1,733	-1,677	-1,613	-1,558	-1,506	-1,445	-1,392	-1,330	-1,272	-1,217	-1,165	-1,107	-1,073	-1,023
Additional Paid-In Capital	0.2%	1,874	1,871	1,866	1,830	1,816	1,808	1,797	1,711	1,700	1,690	1,677	1,665	1,641	1,628	1,606	1,594	1,581	1,568	1,392	1,378	1,355
Accumulated Depreciation	-100.0%	-	17.00	-	-	-	14.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	-100.0%	-	150	145	119	119	119	112	102	102	102	97.00	95.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	120	-	-	-	285	-	-	-	1,600	-	-	-	1,300	-	-	-	1,400	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-487.6%	-9,516	2,455	-9,179	-27,165	-24,900	-37,534	-37,066	-28,373	-43,939	-45,258	-53,166	-62,992	-41,938	-52,554	-42,054	-57,277	-32,935	-26,977	-25,471	-23,108	-49,024
Share Based Compensation	-21.9%	3,375	4,324	6,683	13,900	7,947	10,514	11,198	10,353	10,915	12,888	11,236	11,241	11,486	16,035	11,095	11,114	11,974	11,099	9,704	12,706	17,902
Cashflow From Investing	114.5%	1,278	-8,836	-23,221	13,218	36,834	2,021	-36,047	19,756	10,946	-24,258	21,634	39,697	-4,344	56,789	55,943	32,408	63,815	-126,359	28,627	41,839	34,110
Cashflow From Financing	-94.5%	11.00	199	53,797	319	-208	439	74,942	315	-637	487	-71.00	154,729	883	5,762	524	2,312	507	165,126	3,914	10,846	6,539

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

HRTX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Net product sales	$ 34,670	$ 29,615
Cost of product sales	8,444	16,854
Gross profit	26,226	12,761
Operating expenses:
Research and development	4,608	8,836
General and administrative	14,974	15,834
Sales and marketing	11,442	21,154
Total operating expenses	31,024	45,824
Loss from operations	(4,798)	(33,063)
Other income, net	1,638	295
Net loss	(3,160)	(32,768)
Other comprehensive loss:
Unrealized (losses) gains on short-term investments	(19)	28
Comprehensive loss	$ (3,179)	$ (32,740)
Basic net loss per share	$ (0.02)	$ (0.27)
Weighted average common shares outstanding, basic	151,199	119,246
Diluted net loss per share	$ (0.02)	$ (0.27)
Weighted average common shares outstanding, diluted	151,199	119,246

HRTX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 20,450	$ 28,677
Short-term investments	51,074	51,732
Accounts receivable, net	65,322	60,137
Inventory	42,473	42,110
Prepaid expenses and other current assets	6,584	6,118
Total current assets	185,903	188,774
Property and equipment, net	19,306	20,166
Right-of-use lease assets	4,794	5,438
Other assets	7,884	8,128
Total assets	217,887	222,506
Current liabilities:
Accounts payable	837	3,240
Accrued clinical and manufacturing liabilities	19,943	22,291
Accrued payroll and employee liabilities	7,647	9,224
Other accrued liabilities	43,814	41,855
Current lease liabilities	3,137	3,075
Total current liabilities	75,378	79,685
Non-current lease liabilities	2,045	2,800
Non-current notes payable, net	24,447	24,263
Non-current convertible notes payable, net	149,542	149,490
Other non-current liabilities	241	241
Total liabilities	251,653	256,479
Stockholders' deficit:
Common stock	1,504	1,503
Additional paid-in capital	1,873,910	1,870,525
Accumulated other comprehensive (loss)/income	(6)	13
Accumulated deficit	(1,909,174)	(1,906,014)
Total stockholders' deficit	(33,766)	(33,973)
Total liabilities and stockholders' deficit	$ 217,887	$ 222,506

About Heron Therapeutics Inc

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

CEO	Mr. Craig Alexander Collard
WEBSITE	herontx.com
INDUSTRY	Biotechnology
EMPLOYEES	203

Heron Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Heron Therapeutics Inc? What does HRTX stand for in stocks?

HRTX is the stock ticker symbol of Heron Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Heron Therapeutics Inc (HRTX)?

As of Fri May 17 2024, market cap of Heron Therapeutics Inc is 482.09 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HRTX stock?

You can check HRTX's fair value in chart for subscribers.

What is the fair value of HRTX stock?

You can check HRTX's fair value in chart for subscribers. The fair value of Heron Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Heron Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HRTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Heron Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether HRTX is over valued or under valued. Whether Heron Therapeutics Inc is cheap or expensive depends on the assumptions which impact Heron Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HRTX.

What is Heron Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, HRTX's PE ratio (Price to Earnings) is -5.96 and Price to Sales (PS) ratio is 3.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HRTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Heron Therapeutics Inc's stock?

In the past 10 years, Heron Therapeutics Inc has provided -0.118 (multiply by 100 for percentage) rate of return.